Item 2.02 Results of Operations and Financial Condition.
The information provided in Item 7.01 of this Current Report on Form 8-K is
incorporated in this Item 2.02 by reference.
Item 7.01 Regulation FD Disclosure.
On November 14, 2022, the Company issued a press release announcing its
financial results for the third quarter ended September 30, 2022. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
The information in this Item 7.01 and the information contained in Exhibit 99.1
is furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as may be expressly set forth by specific
reference in any such filing, regardless of any general incorporation language
in the filing.
The Company does not have, and expressly disclaims, any obligation to release
publicly any updates or any changes in its expectations or any change in events,
conditions, or circumstances on which any forward-looking statement is based.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit Index Exhibit No. Description 99.1 Press Release from TherapeuticsMD, Inc., dated November 14, 2022, entitled "TherapeuticsMD Announces Third Quarter 2022 Financial Results." 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
© Edgar Online, source Glimpses